Tauriga Sciences Inc (TAUG)

[Johnny_C]

Me thinks VTGN has an excellent shot at double digits. Just a couple weeks ago SAGE, a company with no sales, shot up $75 a share or an increase of 2 bil market cap on a positive phase 2 trial.

Allergan bought a similar drug of Naurex for 650 mil in cash and 1.2 bil in backend milestones, it is my understanding that some milestones have already been met. Some Allergan analysts state that they will have a depression blockbuster. The downside of the AGN drug is it needs to be administered through intravenous. That means a trip to the doctor and about an hour and a half at the office.

Vtgn drug is oral. The NIH is fully funding phase 2a and Vtgn will kick off phase 2 adjunctive in January.

Recently several positive events occurred,

1. After meeting with the FDA, the FDA approved a new formulation midstream

2. Last week the US patent office gave VTGN a stronger patent from the new formulation

On that news VTGN ran up to 2.5 on 40 million shares, the next day 20 million shares. Previous to that vtgn traded less than 50,000 shares a day.

This could be a huge win in the next 12 months.